NeoTX is a series c plus startup based in Israel. Data sourced from Brouky Intelligence.
About
NeoTX is a clinical-stage biopharmaceutical company developing targeted anticancer immunotherapies utilizing its proprietary Tumor-Targeted Superantigen (TTS) platform.
Stage
series-c-plus
See full investor history, risk signals & comparable companies
Brouky tracks 15,000+ startups with funding rounds, risk analysis, and AI-powered investor matching.
Subscribe to Brouky